Medical News

Hauppauge, NY July 7, 2003 - Infared Sciences Corp., The BreastScan IR uses digital infrared imaging to detect breast cancer signs. The system is highly sensitive (99.1%), and has demonstrated this in over 3 years of testing in screening and oncology applications. A report on the Clinical Study is posted on the company?s web site (address provided below), along with a wealth of other information and photographs. This system is fully automated, employs expert software techniques, and makes an “expert” out of each doctor with its real time “Patient Report”. It is the first system of its kind which identifies the patient’s overall risk, the breast at risk, and specific site in the breast as the most likely location of a cancer.

Thomas DiCicco, President of Infrared Sciences Corp. states, ? Our main focus is improving breast cancer screening, monitoring of treatment, and overall determination of a patient’s breast cancer risk. The system is provided free of charge to qualified doctors. We believe this system can become a key screening tool for women with dense breasts, and may be a good risk indicator for women in the 20-40 year (pre-mammography) age group. We have found that the system accurately indicates sites that can benefit from targeted ultrasound, further improving the early detection process.?

Applications in oncology found that the test output corresponds very well with clinical findings during neo-adjuvant or adjuvant treatment (chemotherapy). Testing at the offices of Dr. Francis Arena, of Arena Oncology Assoc. P.C. in Great Neck, NY, revealed several breast cancer cases where the test was able to predict improvement before it was clinically evident. It also was shown to be particularly useful in monitoring breast cancer patients; in one case the test indicated reoccurrence months before cancer was detected by routine tests.

Infrared imaging has been around a long time, and, even recently, some companies have not had much success in this area. Mr. DiCicco continues, ?We are very different from those in the field. We designed a software program to extract all the best information infrared imaging can produce and combined it in a computer algorithm that is proven robust. We are on the forefront of low cost, non-invasive, in-vivo imaging to help detect the earliest signs of breast cancer with FDA approved technology.?

About Infrared Sciences Corp. (ISC)

Founded in 1999 with the intention to bring new advances in imaging and computer technology to help solve the breast cancer detection problem. Their efforts were demonstrated successful within one year of clinical testing. To date, ISC has provided the BreastScan IR system to doctors in New York City, Long Island, and in Montreal. The Company has over 700 tested patients in its database and is preparing additional clinical evaluation at Cornell University Medical Center and other academic sites. For more information about ISC or a CD on the BreastScan IR Clinical Study, please contact:

Anthony Trotta
Infrared Sciences Corp.
380 Townline Rd.
Hauppauge, NY 11788
631 265 5450

Hauppauge, NY July 7, 2003 - Infared Sciences Corp., The BreastScan IR uses digital infrared imaging to detect breast cancer signs. The system is highly sensitive (99.1%), and has demonstrated this in over 3 years of testing in screening and oncology applications. A report on the Clinical Study is posted on the company?s web site (address provided below), along with a wealth of other information and photographs. This system is fully automated, employs expert software techniques, and makes an “expert” out of each doctor with its real time “Patient Report”. It is the first system of its kind which identifies the patient’s overall risk, the breast at risk, and specific site in the breast as the most likely location of a cancer.

Thomas DiCicco, President of Infrared Sciences Corp. states, ? Our main focus is improving breast cancer screening, monitoring of treatment, and overall determination of a patient’s breast cancer risk. The system is provided free of charge to qualified doctors. We believe this system can become a key screening tool for women with dense breasts, and may be a good risk indicator for women in the 20-40 year (pre-mammography) age group. We have found that the system accurately indicates sites that can benefit from targeted ultrasound, further improving the early detection process.?

Applications in oncology found that the test output corresponds very well with clinical findings during neo-adjuvant or adjuvant treatment (chemotherapy). Testing at the offices of Dr. Francis Arena, of Arena Oncology Assoc. P.C. in Great Neck, NY, revealed several breast cancer cases where the test was able to predict improvement before it was clinically evident. It also was shown to be particularly useful in monitoring breast cancer patients; in one case the test indicated reoccurrence months before cancer was detected by routine tests.

Infrared imaging has been around a long time, and, even recently, some companies have not had much success in this area. Mr. DiCicco continues, ?We are very different from those in the field. We designed a software program to extract all the best information infrared imaging can produce and combined it in a computer algorithm that is proven robust. We are on the forefront of low cost, non-invasive, in-vivo imaging to help detect the earliest signs of breast cancer with FDA approved technology.?

About Infrared Sciences Corp. (ISC)

Founded in 1999 with the intention to bring new advances in imaging and computer technology to help solve the breast cancer detection problem. Their efforts were demonstrated successful within one year of clinical testing. To date, ISC has provided the BreastScan IR system to doctors in New York City, Long Island, and in Montreal. The Company has over 700 tested patients in its database and is preparing additional clinical evaluation at Cornell University Medical Center and other academic sites. For more information about ISC or a CD on the BreastScan IR Clinical Study, please contact:

Anthony Trotta
Infrared Sciences Corp.
380 Townline Rd.
Hauppauge, NY 11788
631 265 5450